Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Inclusion Criteria: * PRE-REGISTRATION INCLUSION CRITERIA * Ability to understand and willingness to sign a written informed consent document and follow study procedures * Willingness to abstain from grapefruit juice, alcohol, and concomitant medications during study * Willingness to employ adequate contraception for men and women of childbearing potential; acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status documented by serum follicle-stimulating hormone (FSH), and/or documentation of surgical sterilization * Body mass index \< 35 kg/m\^2 * Willingness to provide blood and tissue specimens for research purposes * REGISTRATION INCLUSION CRITERIA * Participants must have normal organ function and have normal laboratory findings without clinically significant findings * Satisfactory anesthesia and intestinal preparation, with no findings of advanced adenoma, chronic inflammation, or cancer Exclusion Criteria: * PRE-REGISTRATION EXCLUSION CRITERIA * Previous personal history of advanced adenomas (\>= 1 cm in maximal diameter, \>= 3 in total number, villous morphology, or high-grade dysplasia) or colorectal cancer * Family history of polyposis syndrome (e.g., familial adenomatous polyposis \[FAP\], hereditary non-polyposis colorectal cancer \[HNPCC\]) or colorectal cancer (first degree relatives younger than 60 years old) * History of gastroparesis * History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery * History of celiac disease * Inflammatory bowel disease (Crohn's disease, ulcerative colitis) * Irritable bowel syndrome, chronic constipation, functional bowel disorders, or colonic motility disorder * Any malignancy within 3 years of baseline; participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator * Participants may not be receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide * History of difficulty with colonoscopy or abnormal colorectal anatomy * Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or lactating women * Use of laxatives more than 3 times per week * Intestinal motility agents, histamine-2 inverse agonists (H-2 blockers), or proton pump inhibitors * Current use of \>= 5 cigarettes/day * Current use of \>= 3 alcoholic drinks/day * Use anti-platelet agents within two weeks of anticipated colonoscopy * Use of anti-coagulants within two weeks of anticipated colonoscopy * History of bleeding/coagulation problems * Prior intolerance of or contraindications for the use of sedation or anesthetic agents, which would prevent the safe use of sedation for colonoscopy; this includes allergies to eggs and soy products * Any medical condition judged by the investigator to constitute a risk to safe participation * REGISTRATION EXCLUSION CRITERIA * Colonoscopic finding requiring clinical intervention * Use of any illicit or illegal substances detected by urinary drug screen * Inadequate pre-intervention bowel preparation, as determined by the study physician